Aerodynamic characteristics of nebulized terbutaline sulphate using the next generation impactor (NGI) and CEN method

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 22, Issue 1, 2009, Pages 19-28

  Abdelrahim, Mohamed E ^a,b   Chrystyn, Henry ^c  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b Beni Suef University   (Egypt)

^c UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

Author keywords

CEN method; Cooling; Evaporation; Flow; Nebulizer; Next generation impactor; Terbutaline sulphate

Indexed keywords

TERBUTALINE; TERBUTALINE SULFATE;

AEROSOL; ARTICLE; COMPARATIVE STUDY; COOLING; EVAPORATION; FLOW MEASUREMENT; INTERMETHOD COMPARISON; METHODOLOGY; NEBULIZATION; NEBULIZER; PARTICLE SIZE; ROOM TEMPERATURE;

NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; TERBUTALINE;

EID: 65349131457     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2008.0650     Document Type: Article

References (28)

1. Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, Diot P, Heslop K, and Lannefors L: European Respiratory Society Task Force on the use of nebulizers. European Respiratory Society Guidelines on the use of nebulizers: guidelines prepared by a European Respiratory Society Task Force on the use of nebulizers. Eur Respir J. 2001;18:228-242.
2. Comité-Européen-Normalisation. Respiratory Therapy Equipment - Part 1:Nebulizing System and Their Components. prEN 13544-1. CEN Brussels, Belgium; pp. 33-38, 2001.
3. Marple VA, Olson BA, Santhanakrishan K, Roberts DL, Mitchell JP, and Hudson-Curtis BL: Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L/min. J Aerosol Med. 2004;17:335-343.
4. Dennis JH: Nebulizer efficiency: modeling versus in-vitro testing. Respir Care. 2007;52:1037-1050.
5. Zhou Y, Ahuja A, Irvin CM, Kracko DA, McDonald JD, and Chen Y-S: Medical nebulizer performance: effects of cascade impactor temperature. Respir Care. 2005;50:1077-1082.
6. Dennis JH, and Pieron C: 2004. Quality control and standards in nebulizer performance and use. In: RJ Boe, BR O'Driscoll, and J Dennis (eds). Practical Handbook of Nebulizer Technology, Martin Dunitz, London.
7. British Pharmacopoeia. Preparations for Inhalation. Aerodynamic Assessment of Fine Particles-Fine Particle Dose and Particle Size Distribution (Ph. Eur. method 2.9.18). British Pharmacopoeia, London; A277-A290, 2005.
8. United States Pharmacopeia. Aerosols, nasal sprays, me-tered dose inhalers and dry powder inhalers. US Pharmacopeia 28, 2359-2377.
9. Marple V, Roberts D, and Mitchell J: A proposal for the use of the Next Generation Impactor (NGI) at flow rates between 15 and 30 L/min. Respir Drug Del 2004;IX:701-704.
10. Marple V, Olson B, Santhanakrishnan K, Roberts D, Mitchell J, and Hudson-Curtis B. Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L/min. J Aerosol Med. 2004;17:335-343.
11. Jauernig J, Ohl S, Luber M, and Keller M: Differences in results obtained with the next generation impactor (NGI) for Pulmicort® suspension and according to the CEN standard EN13544-1 for a NaF Solution. Respir Drug Del 2003;XIV. 41-44.
12. Berg E, Svensson JO, and Asking L: Determination of nebulizer droplet size distribution: a method based on impactor refrigeration. J Aerosol Med 2007;20:97-104.
13. Berg E, and Asking L: 2004 Nebulizer droplet size distribution- refrigerated NGI at 15 L/min. Respir Drug Del 2004; IX:361-363.
14. Jauernig J, Ohl S, Knoch M, and Keller M: Effects of the test set-up formulation, and nebulizer type on aerodynamic droplet characteristics. Respir Drug Del 2004;IX:609-612.
15. Dennis J, Berg E, Sandell D, Ali A, Lamb P, Tservistas M, Karlsson M, and Mitchell J: Cooling the NGI - An approach to size a nebulised aerosol more accurately. Pharm Europa Sci Notes 2008;1:27-30.
16. European Directorate for the Quality of medicines (EDQM): Preparations for nebulisation: characterisation, general chapter 2.9.44. Pharmeuropa. 2006;18:280-282.
17. Finlay WH, and Stapleton KW: Undersizing of droplets from a vented nebulizer caused by aerosol heating during transit through an anderson impactor. J Aerosol Sci. 1990;30: 105-109.
18. Fink J, Schmidt D, and Power J: Comparison of a nebulizer using a novel aerosol generator with a standard ultrasonic nebulizer designed for use during mechanical ventilation. Am J Respir Crit Care Med. 2001;163:A127.
19. Berg E, Lamb P, Dennis JH, Tservistas M, and Mitchell J: European Pharmaceutical Aerosol Group (EPAG) Nebuliser Sub-Team: assessment of the need to coat collection cup surfaces of the Next Generation Impactor (NGI) to mitigate droplet bounce. J Aerosol Med. 2007;20:189-190.
20. Berg E, Lamb P, Ali A, Dennis J, Tservistas M, and Mitchell J: Assessment of the need to coat particle collection cups of the NGI to mitigate droplet bounce when evaluating nebuliser-produced droplets. Pharm Europa Sci Notes: 2008;1:21-26.
21. Silkstone VL, Dennis JH, Pieron CA, and Chrystyn H: An investigation of in vitro/in vivo correlations for Salbutamol nebulized by eight systems. J Aerosol Med. 2003;15:251-259.
22. Hinds WC: Aerosol Technology: Properties, Behaviour, and Measurement of Airborne Particles, 2nd ed. Wiley-Interscience, New York, 1999.
23. Johnson MA, Newman SP, and Bloom R: Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma: efficacy and pulmonary deposition. Chest. 1989;96:1-10.
24. Newman SP, and Chan H-K: In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med. 2008;21:77-84.
25. Hess D, Fisher D, Williams P, Poole S, and Kacmarek RM: Medication nebulizer performance: effects of diluent volume, nebulizer flow and nebulizer brand. Chest. 1996;110: 498-505.
26. Clay MM, Pavia D, Newman SP, and Clarke SW: Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 1983;38:755-759.
27. Clay MM, Pavia D, Newman SP, Lennard-Jones T, and Clarke SW: Assessment of jet nebulisers for lung aerosol therapy. Lancet. 1983;2:592-594.
28. Schuschnig U, Hug M, Klopfer E, Knoch M, Keller M. The Next Generation Impactor (NGI): Effects of environment conditions and impactor temperature on particles size measurement of an aqueous aerosol. Respir Drug Del Europe. 2007;311-316.